IL-5/5R targeting MAbs, such as mepolizumab and benralizumab, which have shown favorable safety profiles and effectiveness in both clinical trials and real-world settings, including patients with hypereosinophilic syndrome. Here, IL5 is linked to hypereosinophilic syndrome.